MedPath

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

Phase 2
Completed
Conditions
Stress Urinary Incontinence
Interventions
Drug: Placebo
Registration Number
NCT03241342
Lead Sponsor
GTx
Brief Summary

GTx-024 is an orally bioavailable and tissue-selective nonsteroidal selective androgen receptor modulator (SARM) that has demonstrated androgenic and anabolic activity and is currently being evaluated as a potential treatment for stress urinary incontinence (SUI) in postmenopausal women. Urinary incontinence and pelvic floor disorders are major health problems for women, especially as they age. Pelvic floor muscle relaxation has been found to correlate with lower urinary tract symptoms including SUI. Muscles of the pelvic floor and lower urinary tract are crucial for supporting the pelvic organs and micturition; however, damage to the muscles or lack of hormonal stimulation are thought to contribute to pelvic organ prolapse and urinary incontinence. Although anabolic steroids may increase muscle mass and strength, lack of oral bioavailability and known potential risks have limited their use. Nonsteroidal SARMs have potential to achieve benefits of anabolic steroid therapy (improved muscle mass, cholesterol/triglyceride levels, glucose metabolism, and bone density) with fewer adverse effects, such as hirsutism and acne, in women. Both nonclinical and clinical data suggest that SARMs may provide a new therapeutic option for pelvic floor and lower urinary tract disorders, as both testosterone and its more potent metabolite, dihydrotestosterone, have anabolic effects on muscle.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
491
Inclusion Criteria
  • SUI symptoms of at least 6 months duration
  • Predominant SUI as determined at the Screening Visit using the Medical, Epidemiological, and Social Aspects of Aging (MESA) urinary questionnaire.
  • 24-Hour pad weight > 3 g during the screening period
  • A minimum of 1 and no more than 15 SUI episodes on any single day AND no fewer than 9 total SUI episodes over 3 days during the screening period
  • Positive bladder stress test conducted during the Screening Visit

Key

Exclusion Criteria
  • History of pelvic radiation treatment
  • History of urethral diverticula
  • History of urethral sling or anterior prolapse repair
  • Treatment with urethral bulking agents and/or other SUI procedure or surgery within the 6 months prior to the Screening Visit
  • Known vesicoureteral reflux, vaginal prolapse beyond the introitus, or other significant pelvic floor abnormalities
  • Urinary incontinence of neurogenic etiology
  • Morbidly obese (defined as 100 pounds over ideal body weight, or body mass index 40 or greater)
  • Chronic hepatitis
  • Hepatic cirrhosis
  • Evidence of active infection with hepatitis B or hepatitis C
  • History of human immunodeficiency virus (HIV) infection
  • Subjects with a history of breast or endometrial cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1 mg GTx-024GTx 024Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
3 mg GTx-024GTx 024Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
matching placeboPlaceboStudy drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
Primary Outcome Measures
NameTimeMethod
Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 1212 Weeks

Mean number of subject-reported stress incontinence episodes per day through a responder analysis, where a responder is defined as having a ≥ 50% reduction at the end of treatment (Week 12) compared to baseline in the number of stress incontinence episodes

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (62)

William Beaumont Hospital Urology Research

🇺🇸

Royal Oak, Michigan, United States

Circuit Clinical

🇺🇸

West Seneca, New York, United States

Alliance Urology Specialist PA

🇺🇸

Greensboro, North Carolina, United States

Aventiv Research

🇺🇸

Columbus, Ohio, United States

University of Pennsylvania Health System

🇺🇸

Philadelphia, Pennsylvania, United States

Urology of Virginia

🇺🇸

Virginia Beach, Virginia, United States

Boston Clinical Trials

🇺🇸

Boston, Massachusetts, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

James A Simon MD PC

🇺🇸

Washington, District of Columbia, United States

Urology Center of Alabama

🇺🇸

Homewood, Alabama, United States

Coastal Clinical Research Inc

🇺🇸

Mobile, Alabama, United States

Alaska Clinical Research Center

🇺🇸

Anchorage, Alaska, United States

Medical Research of Florida

🇺🇸

Miami, Florida, United States

Precision Clinical Research

🇺🇸

Lauderdale Lakes, Florida, United States

American Institute of Research

🇺🇸

Whittier, California, United States

Women's Health Specialty Care

🇺🇸

Farmington, Connecticut, United States

Coastal Connecticut Research, LLC

🇺🇸

New London, Connecticut, United States

South Florida Medical Research

🇺🇸

Aventura, Florida, United States

Tampa Bay Medical Research Inc

🇺🇸

Clearwater, Florida, United States

Midland Florida Clinical Research Center LLC

🇺🇸

DeLand, Florida, United States

Lone Star Research Center

🇺🇸

Miami, Florida, United States

Mount Vernon Clinical Research LLC

🇺🇸

Sandy Springs, Georgia, United States

Idaho Urologic Institue

🇺🇸

Meridian, Idaho, United States

Clinical Research Center of Florida

🇺🇸

Pompano Beach, Florida, United States

Clinical Research Prime

🇺🇸

Idaho Falls, Idaho, United States

Women's Health Institution of Illinois

🇺🇸

Oak Lawn, Illinois, United States

First Urology PSC

🇺🇸

Jeffersonville, Indiana, United States

Iowa Clinic

🇺🇸

West Des Moines, Iowa, United States

DelRicht Clinical Research, LLC

🇺🇸

New Orleans, Louisiana, United States

Chesapeake Urology Associates PA

🇺🇸

Hanover, Maryland, United States

Regional Urology

🇺🇸

Shreveport, Louisiana, United States

Women's Clinic of Lincoln

🇺🇸

Lincoln, Nebraska, United States

Bay State clinical Trials

🇺🇸

Watertown, Massachusetts, United States

Accumed Research Associates

🇺🇸

Garden City, New York, United States

Delaware Valley Urology

🇺🇸

Mount Laurel, New Jersey, United States

American Health Research Inc

🇺🇸

Charlotte, North Carolina, United States

Manhattan Medical Research Practice PLLC

🇺🇸

New York, New York, United States

Beyer Research

🇺🇸

Kalamazoo, Michigan, United States

Premier Urology Group, LL

🇺🇸

Edison, New Jersey, United States

Eastern Carolina Women's

🇺🇸

New Bern, North Carolina, United States

Institute for Female Pelvic Medicine

🇺🇸

Allentown, Pennsylvania, United States

Urology Clinics of North Texas

🇺🇸

Dallas, Texas, United States

The Jackson Clinic

🇺🇸

Jackson, Tennessee, United States

Urologic Consultants of Southeastern PA LLP

🇺🇸

Bala-Cynwyd, Pennsylvania, United States

Urology Northwest PS

🇺🇸

Mountlake Terrace, Washington, United States

Elligo - Austin Area OBGYN

🇺🇸

Austin, Texas, United States

Carolina Urologic Research

🇺🇸

Myrtle Beach, South Carolina, United States

Seattle Womens: Health, Research, Gynocology

🇺🇸

Seattle, Washington, United States

Mayo Clinic Arizona

🇺🇸

Phoenix, Arizona, United States

Women's Healthcare Research Corporation

🇺🇸

San Diego, California, United States

Genitourinary Surgical Consultants

🇺🇸

Denver, Colorado, United States

Sheldon J Freedman MD Ltd

🇺🇸

Las Vegas, Nevada, United States

Clinical Trials of Texas Incorporated

🇺🇸

San Antonio, Texas, United States

Urology San Antonio Research PA

🇺🇸

San Antonio, Texas, United States

Urology Associates Research

🇺🇸

Englewood, Colorado, United States

Urological Associates of Southern Arizona

🇺🇸

Tucson, Arizona, United States

The Urology Group

🇺🇸

Cincinnati, Ohio, United States

Bladder Control Center of Connecticut

🇺🇸

Norwalk, Connecticut, United States

Premier Medical Group

🇺🇸

Poughkeepsie, New York, United States

Lawrence Obs Gyn clinical Research

🇺🇸

Lawrenceville, New Jersey, United States

Coastal Carolina Research Center

🇺🇸

Mount Pleasant, South Carolina, United States

Synexus Clinical Research Advantage, Inc. - Wasatch Peak Family Practice

🇺🇸

Layton, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath